Drug intelligence / Profile preview

SGA307

Development stage: Preclinical
Lead developer: BMG Pharma
Modality: Small Molecules
Administration: Intradermal

Overview

SGA307 is a preclinical-stage injectable bioactive booster developed by BMG Pharma for use in aesthetic medicine. Positioned as a skin rejuvenation treatment, it is designed to improve skin quality and hydration through biorevitalization. While specific ingredients and biological targets are not publicly disclosed, the product likely leverages BMG Pharma's core competencies in hyaluronic acid and bioactive complexes to stimulate dermal repair and extracellular matrix production. As a 'bioactive booster,' it is intended to enhance the skin's structural integrity and appearance via intradermal injection.

Brand names: SGA307 Bioactive BoosterSGA-307 Bioactive BoosterSGA 307 Bioactive Booster
Other names: SGA307 Bioactive BoosterSGA-307 Bioactive BoosterSGA 307 Bioactive Booster

Beyond the preview

Go deeper on SGA307.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGA307.

Explore the full profile